Official SEC submissions

Generate Biomedicines SEC Filings

Direct answer

Generate Biomedicines's latest SEC filing is 8-K.

It was filed on November 12, 2026, and 32 recent filings are available.
Each row links directly to the SEC document and filing index.

Get free Generate Biomedicines email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Recent SEC filings

8-K

Current report

Filed:

Report date:

8-K

10-Q

Periodic report

Filed:

Report date:

10-Q

4

Insider transaction

Filed:

Report date:

4

144

Planned securities sale

Filed:

4

Insider transaction

Filed:

Report date:

4

144

Planned securities sale

Filed:

144

Planned securities sale

Filed:

8-K

Current report

Filed:

Report date:

8-K

10-Q

Periodic report

Filed:

Report date:

10-Q

8-K

Current report

Filed:

Report date:

8-K

10-Q

Periodic report

Filed:

Report date:

10-Q

8-K

Current report

Filed:

Report date:

8-K

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

4

Insider transaction

Filed:

Report date:

4

8-K

Current report

Filed:

Report date:

8-K

S-1/A

Registration statement

Filed:

S-1/A

S-1/A

Registration statement

Filed:

S-1/A

S-1

Registration statement

Filed:

S-1

Verified data

Recent filing categories
5
Recent filings
32
SEC CIK
0002100782
Latest filing date
November 12, 2026